| |
Dear Reader,
Today I'm sharing the #1 stock recommendation of my career.
A royalty stock.
Collecting royalties is one of the most lucrative businesses on earth.
It's the definition of what Porter calls "capital efficiency" – where the profits can scale up big time… but the fixed costs are practically zero.
That's why royalty firms have been some of the best investments in the markets, like:
Ligand Pharmaceuticals (LGND), which earns royalties on popular drugs… up 1,681% in the last 7 years. Texas Pacific Land Trust (TPL), which collects royalties on oil-rich land in Texas… up 1,370% since 2011.And the Mesabi Trust (MSB), which collects royalties on a single mine in Minnesota, up 807% just since the beginning of 2016.
And that's exactly the kind of situation I've found today…
It's a new kind of royalty-like business… with tremendous upside in the coming commodity bull market.
I think it could be a 20-bagger, long term.
You see – when you get in on a lucrative royalty stream at an early stage and a dirt-cheap price, the gains can be massive.
In the early '90s, for example, you could have gotten into Royal Gold for 3 cents a share … and racked up gains through today of more than 150,000%.
That's the kind of situation I'm sharing today.
Yet it's trading for only a few dollars per share right now.
To see what I found, click here.
Good Investing,
Dan Ferris
Senior Analyst
Stansberry Research
P.S. I'm not joking when I say this is the hands-down, No. 1 best pick of my career. I've never found anything else like it in nearly 20 years as an analyst… |
|
| |
All contents of this e-mail are copyright 2018 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.
DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.
You're receiving this email at [email protected]. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to [email protected].
To unsubscribe from this mailing, click here: Unsubscribe
|
|
|
